Home Cart Sign in  
Chemical Structure| 1708971-55-4 Chemical Structure| 1708971-55-4

Structure of Roblitinib
CAS No.: 1708971-55-4

Chemical Structure| 1708971-55-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

FGF401, an inhibitor of human fibroblast growth factor receptor 4 (FGFR4, IC50 = 1.1 nM), has potential antineoplastic activity.

Synonyms: FGF-401

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Roblitinib

CAS No. :1708971-55-4
Formula : C25H30N8O4
M.W : 506.56
SMILES Code : O=C(N1CCCC2=C1N=C(C=O)C(CN3C(CN(C)CC3)=O)=C2)NC4=NC=C(C#N)C(NCCOC)=C4
Synonyms :
FGF-401
MDL No. :MFCD31381923
InChI Key :BHKDKKZMPODMIQ-UHFFFAOYSA-N
Pubchem ID :118036971

Safety of Roblitinib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Roblitinib

RTK

Isoform Comparison

Biological Activity

Target
  • FGFR4

    FGFR4, IC50:1.9 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
HCC09-0913 cells 1 µM 24 hours To evaluate the inhibitory effect of FGF401 on the FGF19/FGFR-4 signaling pathway, results showed FGF401 inhibited phosphorylation of FRS-2α and Erk1/2 PMC8080677
MDA-MB-361 0.5 μM Evaluate the anti-tumor effect of Roblitinib on MDA-MB-361 cells, results showed Roblitinib significantly inhibited cell proliferation PMC9106694
MDA-MB-453 0.5 μM Evaluate the anti-tumor effect of Roblitinib on MDA-MB-453 cells, results showed Roblitinib significantly inhibited cell proliferation PMC9106694
AU565 0.5 μM Evaluate the anti-tumor effect of Roblitinib on AU565 cells, results showed Roblitinib significantly inhibited cell proliferation PMC9106694
BT474 0.5 μM Evaluate the anti-tumor effect of Roblitinib on BT474 cells, results showed Roblitinib significantly inhibited cell proliferation PMC9106694
SKBR3 0.5 μM Evaluate the anti-tumor effect of Roblitinib on SKBR3 cells, results showed Roblitinib significantly inhibited cell proliferation PMC9106694
MKN45 cells 20 μM 24 hours Roblitinib inhibits FGFR4 kinase activity and reverses the pro-oncogenic effects of FGF19 and LIF on MKN45 cells. PMC11090936

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c nude mice RSKBR3 and MDA-MB-361 tumor models Oral 30 mg/kg Evaluate the anti-tumor effect of Roblitinib in vivo, results showed Roblitinib significantly inhibited tumor growth PMC9106694
Mice HCC25-0705A xenograft model Oral 20, 30, and 40 mg/kg Twice daily for indicated days To evaluate the dose-response of FGF401, results showed 30 mg/kg FGF401 significantly inhibited tumor growth PMC8080677

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.97mL

0.39mL

0.20mL

9.87mL

1.97mL

0.99mL

19.74mL

3.95mL

1.97mL

References

 

Historical Records

Categories